BACKGROUND: A polymorphism near the IL28B gene has been shown to be associated with virologic response to antiviral treatment in HCV-infected patients. The predictive value of interferon-gamma inducible protein 10 (IP10) on treatment outcome has been described in HCV patients. Data on combining these predictors in HIV-HCV-coinfected patients are not available. METHODS: Virologic parameters, IL28B single nucleotide polymorphisms (SNP) and pretreatment serum IP10 were determined in HIV-HCV-coinfected patients having completed antiviral therapy with pegylated interferon/ribavirin. RESULTS: A total of 72 HIV-HCV-coinfected patients were included in the study; 68% had HCV genotype (GT)-1/4 and 32% had HCV GT-2/3 infections. Rapid virologic response (63% vs. 28%; P = 0·023) and sustained virologic response (SVR: 81% vs. 51%; P = 0·008) rates were significantly higher in C/C vs. non-C/C patients. Patients with low pretreatment IP10 levels (< 400 pg/mL) achieved significantly higher SVR rates than patients with high (> 400 pg/mL) IP10 levels (78% vs. 13%; P < 0·0001). C/C SNP and low IP10 levels were associated with higher SVR rates in both patients with GT-1/4 and GT-2/3. The C/C patients with low IP10 achieved SVR rates of 97% compared with SVR rates of 9% in non-C/C patients with high IP10. CONCLUSION: The IL28B SNP influences rapid viral response, relapse rates and SVR. The combination of IL28B and IP10 represents a predictive model of SVR in HIV-HCV coinfection.
BACKGROUND: A polymorphism near the IL28B gene has been shown to be associated with virologic response to antiviral treatment in HCV-infectedpatients. The predictive value of interferon-gamma inducible protein 10 (IP10) on treatment outcome has been described in HCV patients. Data on combining these predictors in HIV-HCV-coinfectedpatients are not available. METHODS: Virologic parameters, IL28B single nucleotide polymorphisms (SNP) and pretreatment serum IP10 were determined in HIV-HCV-coinfectedpatients having completed antiviral therapy with pegylated interferon/ribavirin. RESULTS: A total of 72 HIV-HCV-coinfectedpatients were included in the study; 68% had HCV genotype (GT)-1/4 and 32% had HCV GT-2/3 infections. Rapid virologic response (63% vs. 28%; P = 0·023) and sustained virologic response (SVR: 81% vs. 51%; P = 0·008) rates were significantly higher in C/C vs. non-C/C patients. Patients with low pretreatment IP10 levels (< 400 pg/mL) achieved significantly higher SVR rates than patients with high (> 400 pg/mL) IP10 levels (78% vs. 13%; P < 0·0001). C/C SNP and low IP10 levels were associated with higher SVR rates in both patients with GT-1/4 and GT-2/3. The C/C patients with low IP10 achieved SVR rates of 97% compared with SVR rates of 9% in non-C/C patients with high IP10. CONCLUSION: The IL28B SNP influences rapid viral response, relapse rates and SVR. The combination of IL28B and IP10 represents a predictive model of SVR in HIV-HCV coinfection.
Authors: Chelsey J Judge; Johan K Sandberg; Nicholas T Funderburg; Kenneth E Sherman; Adeel A Butt; Minhee Kang; Alan L Landay; Michael M Lederman; Donald D Anthony Journal: J Acquir Immune Defic Syndr Date: 2016-11-01 Impact factor: 3.731
Authors: María A Jiménez-Sousa; Amanda Fernández-Rodríguez; María Guzmán-Fulgencio; Mónica García-Álvarez; Salvador Resino Journal: BMC Med Date: 2013-01-08 Impact factor: 8.775
Authors: Shehnaz K Hussain; Asieh Golozar; Daniel P Widney; Giovanna Rappocciolo; Sudhir Penugonda; Jay H Bream; Otoniel Martínez-Maza; Lisa P Jacobson Journal: AIDS Res Hum Retroviruses Date: 2020-12-29 Impact factor: 1.723
Authors: Heinz Zoller; Annina Jenal; Albert F Staettermayer; Sebastian Schroecksnadel; Peter Ferenci; Dietmar Fuchs Journal: Pharmaceuticals (Basel) Date: 2015-06-18
Authors: Bernhard Scheiner; Mattias Mandorfer; Philipp Schwabl; Berit Anna Payer; Theresa Bucsics; Simona Bota; Maximilian C Aichelburg; Katharina Grabmeier-Pfistershammer; Albert Stättermayer; Peter Ferenci; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger Journal: PLoS One Date: 2015-11-23 Impact factor: 3.240